Genfit (GNFT) has released an update.
GENFIT, a leader in liver disease therapeutics, has published its 2024 Extra-Financial Performance Report, highlighting its commitment to social responsibility and its alignment with new European non-financial disclosure standards. The company’s CSR efforts have been recognized with several awards, and it continues to focus on creating long-term value through sustainable practices. GENFIT’s robust R&D portfolio targets rare and life-threatening liver diseases, with a significant focus on Acute-on-Chronic Liver Failure (ACLF) and other serious conditions.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
